

**BUKTI  
SUBMIT  
MANUSKRIP**

---

## IJPHARM-D-22-03252 - Confirming your submission to International Journal of Pharmaceutics

1 message

---

International Journal of Pharmaceutics <em@editorialmanager.com>

Fri, Dec 2, 2022 at 1:53 PM

Reply-To: International Journal of Pharmaceutics <support@elsevier.com>

To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Re: Polymeric hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from direct-compressed tablet reservoir for potential improvement of pulmonary hypertension therapy

Research Paper

Andi Maqhfirah Nurul Fitri; Diany Elim; Muhammad Alif Sya'ban Mahfud; Nurul Aisha Fitri Sultan; Mesakh Diki Saputra; Nur Afika; Rissa Ardita Friandini; Nana Juniarti Natsir Djide; Andi Dian Permana

Dear Dr. Permana,

Your submission entitled "Polymeric hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from direct-compressed tablet reservoir for potential improvement of pulmonary hypertension therapy" has been received by International Journal of Pharmaceutics. It has been assigned the following manuscript number: IJPHARM-D-22-03252.

You may check on the progress of your paper by logging on to the Editorial Manager as an author. The URL is <https://www.editorialmanager.com/ijpharm/>.

Your username is: andipermana

If you need to retrieve password details, please go to: <https://www.editorialmanager.com/ijpharm/l.asp?i=812871&l=AR2F4KWY>

Thank you for submitting your work to this journal.

IJP is the 2nd most cited journal in the category "Pharmacy & Pharmacology" (out of 279 journals) (Clarivate 2022).

IJPX is the open access companion journal of IJP. It received its first impact factor this year: 5.679.

Both journals are the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation.

Kind regards,

Editorial Manager  
International Journal of Pharmaceutics

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

This journal uses the Elsevier Article Transfer Service. This means that if an editor feels your manuscript is more suitable for an alternative journal, then you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. For more details see the journal guide for authors.

#AU\_IJPHARM#

To ensure this email reaches the intended recipient, please do not delete the above code

---

In compliance with data protection regulations, you may request that we remove your personal registration details at

any time. (Use the following URL: <https://www.editorialmanager.com/ijpharm/login.asp?a=r>). Please contact the publication office if you have any questions.

**BUKTI**  
**ACCEPTED**

---

## Your Submission

1 message

---

**International Journal of Pharmaceutics** <em@editorialmanager.com>  
Reply-To: International Journal of Pharmaceutics <support@elsevier.com>  
To: Andi Dian Permana <andi.dian.permana@farmasi.unhas.ac.id>

Fri, Dec 23, 2022 at 1:45 AM



Ms. Ref. No.: IJPHARM-D-22-03252

Title: Polymeric hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from direct-compressed tablet reservoir for potential improvement of pulmonary hypertension therapy  
International Journal of Pharmaceutics

Dear Dr. Permana,

I am pleased to confirm that your paper Polymeric hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from direct-compressed tablet reservoir for potential improvement of pulmonary hypertension therapy has been accepted for publication in International Journal of Pharmaceutics.

Upon transfer of your paper to our production department, your article proof will be created and sent to you for checking. You will also be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact you.

Thank you for submitting your work to this journal.

IJP is the 2nd most cited journal in the category "Pharmacy & Pharmacology" (out of 279 journals) (Clarivate 2022).

IJPX is the open access companion journal of IJP. It received its first impact factor this year: 5.679.

Both journals are the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation.

We encourage authors of original research papers to share the research objects – including raw data, methods, protocols, software, hardware and other outputs – associated with their paper. More information on how our open access Research Elements journals can help you do this is available at [https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec\\_em\\_research\\_elements\\_email](https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email).

With kind regards,

Abdul W Basit, PhD  
Editor  
International Journal of Pharmaceutics

Reviewer #1: The manuscript presents an interesting application of microneedle arrays for sildenafil delivery. The system used is not novel but the application described here has not been described before. Moreover, the paper contains a thorough characterisation of the materials, microneedles and tablets. Therefore I think it should be accepted for publication after minor revision.

Specific points:

1. During the swelling study it can be seen that after 24h there is some weight loss. Could you please comment on this? This might indicate that some of the polymer from the hydrogel is been released. The polymers used here are

biocompatible so this will not be a problem but I think the authors have to add some explanation about this in the discussion. Additionally, the authors presented statistical analysis from the swelling study but the graphs did not show error bars. Could you please include them?

2. Directly compressed tablets are prepared using microcrystalline cellulose as binder. Is this compound going to be administered with the drug into the skin? If so is this a problem? What about biocompatibility of MCC? Are there any other parenteral product containing MCC? I assume that this product will not permeate as it is not soluble but these points should be mentioned in the discussion.

#AU\_IJPHARM#

To ensure this email reaches the intended recipient, please do not delete the above code



---

*In compliance with data protection regulations, you may request that we remove your personal registration details at any time. ([Remove my information/details](#)). Please contact the publication office if you have any questions.*